GAINESVILLE, Fla.--(BUSINESS WIRE)--BioMonde, LLC, a wound care company specializing in biosurgical debridement, has announced that their groundbreaking debridement product, BioBag, is now available for patient use in the United States. The patented biosurgical medical device, BioBag, will be supplied for the first time to clinicians across all 50 US states, DC and Puerto Rico.
BioBag – debriding with speed and precision
BioBag is the first of its kind, utilizing all the benefits of biosurgery in an easy-to-use contained dressing. Ease of application, rapid debridement, and inexpensive product cost make BioBag a promising debridement solution for non-healing wounds. The unprecedented delivery system allows clinicians to debride wounds with precision while ensuring containment and patient acceptance. BioBag is indicated for the debridement of a wide variety of wounds including pressure ulcers, neuropathic ulcers, venous stasis ulcers and non-healing traumatic or surgical wounds. BioBag is currently the only FDA cleared contained biosurgical dressing on the market.
The challenge of treating non-healing wounds
In the US the vastly increasing levels of diabetes combined with an aging population means that the number of wounds that are unable to heal naturally is increasing significantly.
“Many of the debridement options currently available do not actively, and selectively, remove bacterial burden and all devitalized tissue from a wound. Biosurgery is unique. The wound size does not increase past the level of damaged tissue and nothing unviable is left behind meaning that effective proliferation can take place.” confirms Katy Nicell, Product Manager at BioMonde.
BioMonde, expanding its European success to the US
Since 1994 BioMonde has manufactured and supplied Larval Therapy in Europe and the UK. BioMonde has manufacturing facilities in; Bridgend, Wales, Hamburg, Germany and Gainesville, Florida. BioMonde are dedicated to providing successful outcomes for patients and clinicians and are excited to be bringing the innovative concept of BioBag to the US wound care market.
“Historically, bio-surgery was reserved for the most challenging wounds that were not responding to conventional treatment. In Europe and the UK, we have proven that the early inclusion of BioBag into the routine debridement practice of non-healing wounds, enables rapid results to be achieved in a cost-efficient manner.” states Gareth Kempson, CEO BioMonde.
For product information please visit www.biomonde.com
BioBag is a prescription only medical device and more information on the warnings, side effects, indications and contraindications can be found by visiting www.biomonde.com
